Quince Therapeutics, Inc. (NASDAQ:IRLA) Stock Short Interest Jumps 158.1%

Quince Therapeutics, Inc. (NASDAQ:IRLA) was the target of a large increase in short interest in the month of October. As of October 15th, there was short interest totaling 154,736 shares, an increase of 158.1% from the September 30th total of 59,944 shares. Approximately 16.1% of the shares of the company are sold short. Based on an average daily volume of 46,846 shares, the days-to-cover ratio is presently 3.3 days.

Analyst Ratings Changes

IRLA has been the subject of a number of recent research reports. Weiss Ratings initiated coverage on Quince Therapeutics in a research note on Tuesday, October 13th. They set a “sell (d-)” rating for the company. Raymond James Financial raised Quince Therapeutics to a “moderate buy” rating in a research note on Friday, October 9th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold”.

Quince Therapeutics Price Performance

NASDAQ IRLA traded down $1.34 during trading on Thursday, reaching $31.62. 64,261 shares of the company’s stock traded hands, compared to its average volume of 80,308. Quince Therapeutics has a 12-month low of $15.10 and a 12-month high of $909.98.

About Quince Therapeutics

Quince Therapeutics is a clinical-stage biotechnology company focused on developing treatments for rare diseases with significant unmet medical needs. The company’s primary program is EryDex, an investigational therapy designed to deliver dexamethasone through a patient’s own red blood cells.

EryDex is being evaluated for the treatment of ataxia-telangiectasia, a rare inherited disorder that can cause progressive neurological impairment, immune-system problems and other serious complications.